Clinical trial · Interventional
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON ALPHA
NCT00002847CI-TRIAL-00013103unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aldesleukin | Biological | Aldesleukin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
| recombinant interferon alfa | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven renal cell cancer that is metastatic * No greater than 50% estimated hepatic replacement by tumor on CT or MRI * No symptomatic involvement of the CNS or a major nerve * Measurable disease required * Ineligible for treatment with low-dose interleukin-2 on another CMC protocol PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 50%-100% Life expectancy: * More than 3 months Hematopoietic: * No coagulopathy (i.e., platelet count less than 80,000/mm3) Hepatic: * AST and ALT no greater than 5 times normal Renal: * Creatinine less than 4.0 mg/dL Cardiovascular: * No symptomatic angina * No untreated coronary artery disease * No refractory arrhythmia * No abnormal left ventricular function Pulmonary: * No dyspnea on minimal exertion Other: * No site of ongoing bleeding * No systemic infection * No HIV antibody * No HBsAg * No requirement for steroids * No psychiatric disease that precludes informed consent or protocol treatment * No second malignancy except: * Basal cell skin carcinoma * Carcinoma in situ of the cervix * Not pregnant or nursing * Effective contraception required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy * No prior interleukin-2 Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * At least 28 days since prior treatment for renal cell cancer
References
Publications (0)
Data not yet available
No reference posted for this study.